A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (MicroGeneSys)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]